Nucleic Acid-Based Anti-CRISPR Inhibitors of Cas9

基于核酸的 Cas9 抗 CRISPR 抑制剂

• 批准号: 10864412
• 负责人: Keith Thomas Gagnon
• 金额: $ 24.19万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-05 至 2024-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10864412
• 关键词: Address; Affinity; Animal Model; Animals; Antibiotics; BCAR1 gene; Binding; Biochemical; Biological Models; Biomedical Research; Breathing; CRISPR therapeutics; CRISPR/Cas technology; Campylobacter jejuni; Cell model; Cells; Chemicals; Chemistry; Chimeric Proteins; Clustered Regularly Interspaced Short Palindromic Repeats; DNA; Dangerousness; Development; Diagnostic; Engineering; Enzymes; Exercise; Gene Expression Regulation; Generations; Genes; Genetic; Genome; Genome engineering; Goals; Guide RNA; Health; Human; In Vitro; Length; Light; Measures; Mediating; Methods; Modeling; Modification; Nucleic Acids; Nucleotides; Organism; Pharmaceutical Preparations; Property; Proteins; Safety; Staphylococcus aureus; Streptococcus pyogenes; Structure; Substrate Specificity; System; Technology; Testing; Therapeutic; Therapeutic Research; Time; Translating; chemical conjugate; chemical synthesis; design; enzyme activity; improved; inhibitor; microbiota; model building; model organism; mutant; new technology; novel; novel strategies; novel therapeutics; nuclease; rational design; side effect; small molecule; success; synthetic biology; tool

PROJECT SUMMARY Sophisticated, facile, and potent inhibitors of Cas enzymes that are simple to use are still a major missing tool for CRISPR-based biomedical and therapeutic research. The rationale for CRISPR-Cas inhibitors includes a need for more efficient generation of model cells and organisms, the threat of dangerous off-target editing in CRISPR-based therapeutics, and the desire for more precise control over Cas enzyme activity in synthetic biology and diagnostics applications. Methods and modified Cas enzymes have been developed to help address these issues and other shortcomings of CRISPR-Cas systems, particularly Cas9 from Streptococcus pyogenes (SpCas9). These include Cas9 mutants with lower off-target activity and Cas9 mutants and protein fusions that allow small molecule or light-based activation of Cas9. However, these modifications typically have a concomitant decrease in on-target activity and do not address the need for rapid and specific shut-down of Cas9. Despite improvements to Cas enzymes, the need for specific, broadly applicable, and easy-to-use inhibitors will remain a necessary tool that is not available. Small molecules that can inhibit Cas9 may take significant effort to develop and potentially come with downsides, including their own off-target effects and inadvertent impacts on the organism’s microbiota, possibly similar to antibiotic side-effects. Natural anti-CRISPR proteins have recently been discovered that bind Cas9 and other Cas proteins with high affinity. While promising as inhibitors, they are too large to possess drug-like properties and their minimization or optimization is not an obvious exercise. They must be genetically encoded for use in cells or organisms. However, they provide inspiration for the design of a new class of CRISPR-Cas inhibitors. Here we propose to develop a new technology, nucleic acid-based (NAB) inhibitors of Cas9 enzymes. These molecules are smaller than natural anti-CRISPR proteins but can bind with similar affinity, be chemically synthesized, and be readily introduced into cells with common methods. In this project, we will develop NAB inhibitor technology by optimizing their size, chemistry, binding affinity, inhibitory activity, and cellular stability. We will further develop methods and molecules that facilitate direct, carrier-free delivery and timed-release of NAB inhibitors. The resulting NAB inhibitors are expected to be broadly applicable and straightforward to use for diverse biomedical research. We expect NAB inhibitors to become valuable fail-safe inhibitors to overcome the critical safety hurdles in CRISPR-based therapeutics.

项目总结

项目成果

Binding to the conserved and stably folded guide RNA pseudoknot induces Cas12a conformational changes during ribonucleoprotein assembly.

• DOI: 10.1016/j.jbc.2023.104700
• 发表时间: 2023-05
• 期刊: JOURNAL OF BIOLOGICAL CHEMISTRY
• 影响因子: 4.8
• 作者: Sudhakar, Sruthi;Barkau, Christopher L.;Chilamkurthy, Ramadevi;Barber, Halle M.;Pater, Adrian A.;Moran, Sean D.;Damha, Masad J.;Pradeepkumar, P. I.;Gagnon, Keith T.
• 通讯作者: Gagnon, Keith T.

Small nucleic acids and the path to the clinic for anti-CRISPR.

• DOI: 10.1016/j.bcp.2021.114492
• 发表时间: 2021-07
• 期刊: Biochemical pharmacology
• 影响因子: 5.8
• 作者: Barkau CL;O'Reilly D;Eddington SB;Damha MJ;Gagnon KT
• 通讯作者: Gagnon KT

Gene editing with CRISPR-Cas12a guides possessing ribose-modified pseudoknot handles.

• DOI: 10.1038/s41467-021-26989-z
• 发表时间: 2021-11-15
• 期刊: Nature communications
• 影响因子: 16.6
• 作者: Ageely EA;Chilamkurthy R;Jana S;Abdullahu L;O'Reilly D;Jensik PJ;Damha MJ;Gagnon KT
• 通讯作者: Gagnon KT